|Description||Delanzomib, also known as CEP-18770, is An orally bioavailable synthetic P2 threonine boronic acid inhibitor of the chymotrypsin-like activity of the proteasome, with potential antineoplastic activity. Proteasome inhibitor CEP 18770 represses the proteasomal degradation of a variety of proteins, including inhibitory kappaBalpha (IkappaBalpha), resulting in the cytoplasmic sequestration of the transcription factor NF-kappaB; inhibition of NF-kappaB nuclear translocation and transcriptional up-regulation of a variety of cell growth-promoting factors; and apoptotic cell death in susceptible tumor cell populations. In vitro studies indicate that this agent exhibits a favorable cytotoxicity profile toward normal human epithelial cells, bone marrow progenitors, and bone marrow-derived stromal cells relative to the proteasome inhibitor bortezomib. The intracellular protein IkappaBalpha functions as a primary inhibitor of the proinflammatory transcription factor NF-kappaB.|
|Current Developer||Cephalon & Cell Therapeutics.|
ONX 0914 is an immunoproteasome inhibitor with potential treatment applications in autoimmune disorders, such as rheumatoid arthritis, inflammatory bowel diseas...
Epoxomicin is a potent anti-tumor agent isolated from Actinomycetes that is used as a selective and irreversible inhibitor of the 20S proteasome. It inhibits pr...
Delanzomib, also known as CEP-18770, is An orally bioavailable synthetic P2 threonine boronic acid inhibitor of the chymotrypsin-like activity of the proteasom...
AM 114 is an inhibitor of chymotrypsin-like activity of the 20S proteasome. In addition, AM-114 shows anticancer activity, It can inhibit cell growth in human c...
MG-132(S,R,S) is a reversible, cell permeable and selective tripeptide aldehyde proteasome inhibitor (IC50 = 0.22 μM), the most potent stereoisomer of MG-132. I...
Carfilzomib is a tetrapeptide epoxyketone and an analog of epoxomicin, acting as a selective proteasome inhibitor, such as the chymotrypsin-like β5 subunit of t...
The citrate salt form of Ixazomib which is a proteasome inhibitor. It is considered a rollover Phase II trial against multiple myeloma, amyloidosis and lymphoma...
Cysteine Protease inhibitor
Cysteine Protease inhibitor is a inhibitor of cysteine protease.
PD 151746 is a selective, cell-permeable calpain inhibitor with Ki of 0.26 μM for μ-Calpain, about 20-fold selectivity over m-calpain.
RA190, a bis-benzylidine piperidon, is a novel potent and selective inhibitor of proteasome ubiquitin receptor RPN13/ADRM1. RA190 stabilized targets of human pa...
VR23 is a potent and selective inhibitor of trypsin-like proteasomes (IC50 = 1 nmol/L), chymotrypsin-like proteasomes (IC50 = 50-100 nmol/L), and caspase-like p...
MG-132 is a potent Proteasome inhibitor with potential anticancer activity. MG-132 induces MCPIP1 expression; induces C6 glioma cell apoptosis via oxidative str...
MG-101, also known as Calpain Inhibitor I and ALLN, is a calpain inhibitor (IC50 = 0.09 μM) that activates p53-dependent apoptosis in tumor cell lines. Activiti...
MLN-2238 is the biologically active form of MLN9708. MLN2238 has an improved pharmacodynamic profile and antitumor activity compared with bortezomib in both OCI...
Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM.
PI-1840 potently inhibits proteasomal CT-L activity with IC50 of 0.37 μM in intact human MDA-MB-468 cancer cells, and inhibits proliferation/survival of human M...
PMSF is an irreversible serine/cysteine protease inhibitor.
Oprozomibm, also known as ONX 0912 and PR 047, is an orally bioavailable proteasome inhibitor with potential antineoplastic activity. ONX 0912 inhibits the act...